Tiziana's two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world, with Phase 2 applications in a wide range of autoimmune and inflammatory diseases including nonalcoholic steatohepatitis, ulcerative colitis, multiple sclerosis, type-1 diabetes, Crohn's disease, psoriasis and rheumatoid arthritis.
Cyborg Score Rationale
Tiziana has innovative drug delivery technology and promising clinical candidates in large markets, but faces typical early-stage biotech challenges including low stock price ($1.35 as of May 18, 2026), past NASDAQ compliance issues, and limited near-term catalysts visible in available data. Cash position and path to revenue remain unclear.
Top Insights
Novel non-IV delivery routes (nasal, oral, inhaled) for monoclonal antibodies represent significant competitive advantage in immunotherapy market
Foralumab's broad clinical application potential spans oncology and multiple autoimmune/inflammatory indications with large addressable markets
Company pursuing spinout of IL-6 receptor asset (TZLS-501) suggesting strategic focus realignment and potential value unlock
Safety data on intranasal foralumab shows strong tolerability profile with no serious drug-related adverse events after 37.4 patient-years of exposure
Named Competitors
Remicade/other TNF inhibitors — Established anti-inflammatory biologics for autoimmune diseases
Ocrevus — Anti-CD20 monoclonal antibody for multiple sclerosis
Imraldi/Humira biosimilars — TNF inhibitors for rheumatoid arthritis and autoimmune indications
Recent Developments
(May 2026) Positive clinical data announced for intranasal Foralumab in non-active secondary progressive multiple sclerosis
(2026) Publication of positive data demonstrating intranasal anti-CD3 antibody attenuates Long COVID neuroinflammation and improves cognitive function
(2026) Reported reduced brain inflammation in multiple system atrophy patients treated with intranasal Foralumab
Open the full interactive Tiziana Life Sciences Ltd report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.